Johnson & Johnson Reports Q1 Revenue of $24.1 Billion, Beats Expectations and Raises Full-Year Guidance

Economic Observer NetworkJohnson & Johnson's Q1 2026 Earnings Report, released on April 14, 2026, highlights the following key points:

Performance and Operation Status

Johnson & Johnson's Q1 Sales Reach $24.06 Billion ($24.1 Billion as Reported by Some), Up 9.9% Year-on-Year, Exceeding FactSet Analysts' Average Estimate of $23.62 BillionAdjusted earnings per share were $2.70, also exceeding market expectations.。

Business Progress

During the reporting period, the revenue from the innovative drug business increased by 11.2% year-on-year, reaching 15.43 billion US dollars.The growth was mainly driven by anticancer drugs and antidepressants: Oncology business revenue increased by 22.8% year-over-year, with the multiple myeloma drug daratumumab (Darzalex) achieving sales of $3.964 billion, growing by 22.5%; CAR-T therapy Carvykti's sales surged by 62.1%. In the neuroscience business, the antidepressant Spravato’s sales grew by over 46%. These strong growth figures successfully offset the impact of a significant 60% drop in sales of the blockbuster drug Stelara due to patent expiration.。

Business Progress

Medical device sales reached $8.64 billion, a year-on-year increase of 7.7%, mainly driven by products such as cardiovascular and ophthalmology.。

Company Performance Goals

Based on a strong start in the first quarter, Johnson & Johnson has raised its full-year performance forecast for 2026. The company now expects total annual sales to be between $100.3 billion and $101.3 billion, with adjusted earnings per share projected to be between $11.45 and $11.65, both representing an increase from previous guidance.This marks the company's annual revenue is expected to break through the 100 billion US dollar mark for the first time.

Product Development Progress

The company welcomed the milestone progress of Icotyde, the world's first oral IL-23R-targeted peptide, being approved by the FDA for psoriasis during the quarter, injecting new momentum into future growth.。

The above content is based on publicly available information and does not constitute investment advice.